Europe/India/Near East USA Asia
Bachem AG Bachem Americas, Inc. Bachem Japan K.K.
Hauptstrasse 144 3132 Kashiwa Street AREA Shinagawa, 13F
4416 Bubendorf - Switzerland Torrance, CA 90505 - USA Tokyo 108-0075 - Japan
Tel +41 58 595 2021 Tel +1 888 422 2436 Tel +81 3 4405 3141
Fax +41 58 595 2040 Tel +1 888 4BACHEM Email sales.jp@bachem.com
Email sales.ch@bachem.com Fax +1 310 539 9428  
  E-mail sales.us@bachem.com  

L-NMMA ACETATE 250 mg/VIAL (CLINALFA® BASIC)

L-NMMA Acetate 250 mg/vial (Clinalfa basic)

U-1090, 4056509

 
Synonym

L-NMA

 
Sequence

H-Arg(Me)-OH acetate salt

 
To be used in approved clinical trials only
 
Active Substance

L-NMMA inhibits the synthesis of nitric oxide (NO) in a dose-dependent and enantio-specific fashion. Intravenous or intra-arterial injections of L-NMMA produce a powerful and prolonged vasoconstrictor effect, which can be reversed by L-Arg in a dose-dependent manner.

 
Literature References

A considerable number of publications on Clinalfa products used in clinical trials are available. The most important publications are listed here.
 

 
Note

This product is also available in research grade quality (non GMP)
 

E-3745

H-Arg(Me)-OH
(L-NMMA, Tilarginine, Targinine)